Pembrolizumab plus chemotherapy in persistent, recurrent, or metastatic cervical cancer: A KEYNOTE-826 subgroup analysis

被引：0

作者：

Baron-Hay, Sally ^{[1
]}

Tewari, Krishnansu S. ^{[2
]}

Colombo, Nicoletta ^{[3
,4
]}

Monk, Bradley J. ^{[5
]}

Dubot, Coraline ^{[6
,7
]}

Valeria Caceres, M. ^{[8
]}

Hasegawa, Kosei ^{[9
]}

Shapira-Frommer, Ronnie ^{[10
]}

Salman, Pamela ^{[11
]}

Yanez, Eduardo ^{[12
]}

Gumus, Mahmut ^{[13
]}

Olivera Hurtado de Mendoza, Mivael ^{[14
]}

Samouelian, Vanessa ^{[15
]}

Castonguay, Vincent ^{[16
]}

Arkhipov, Alexander ^{[17
]}

Frentzas, Sophia ^{[18
]}

Tekin, Cumhur ^{[19
]}

Li, Kan ^{[19
]}

Toker, Sarper ^{[19
]}

Keefe, Stephen M.

Lorusso, Domenica ^{[20
,21
]}

机构：

[1] Royal North Shore Hosp, Northern Sydney Canc Ctr, St Leonards, NSW, Australia

[2] Univ Calif Irvine, Obstet & Gynecol, Orange, CA USA

[3] IRCCS, Gynecol Oncol, European Inst Oncol, Milan, Italy

[4] Univ Milano Bicocca, Milan, Italy

[5] Creighton Univ, Coll Med, Gynecol Oncol, Sch Med,Univ Arizona, Phoenix, AZ USA

[6] Inst Curie St Cloud, Oncol Med, Paris, France

[7] GINECO, Paris, France

[8] Inst Oncol Angel H Roffo, Med Oncol, Buenos Aires, DF, Argentina

[9] Saitama Med Univ, Gynecol Oncol, Int Med Ctr, Hidaka, Japan

[10] Sheba Med Ctr, Ella Lemelbaum Inst Immuno Oncol, Ramat Gan, Israel

[11] Oncovida Canc Ctr, Med Oncol, Providencia, Chile

[12] Univ La Frontera, Med Oncol, Temuco, Chile

[13] Istanbul Medeniyet Univ, Prof Dr Suleyman Yalcin City Hosp, Istanbul, Turkey

[14] Inst Nacl Enfermedades Neoplas, Med Oncol, Lima, Peru

[15] Univ Montreal, Ctr Rech Univ Montreal CRCHUM, Ctr Hosp Univ Montreal CHUM, Gynecol Oncol, Montreal, PQ, Canada

[16] Univ Laval, Ctr Hosp Univ Quebec, Med Oncol, Quebec City, PQ, Canada

[17] Minist Hlth Russian Federat, Oncol & Chem Therapy, Med Rehabil Ctr, Moscow, Russia

[18] Monash Hlth, Monash Med Ctr, Clayton, Vic, Australia

[19] Merck & Co Inc, Oncol, Kenilworth, NJ USA

[20] Fdn Policlin Univ A Gemelli, Gynaecol Oncol Unit, IRCCS, Rome, Italy

[21] Univ Cattolica Sacro Cuore, Rome, Italy

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

188

引用

页码：117 / 117

页数：1

共 50 条

[1] Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent, or metastatic cervical cancer: KEYNOTE-826
Yonemori, Kan
Nishio, Shin
Usami, Tomoka
Minobe, Shinichiro
Yunokawa, Mayu
Iwata, Takashi
Okamoto, Aikou
Aoki, Yoichi
Itamochi, Hiroaki
Takekuma, Munetaka
Harano, Kenichi
Yamamoto, Keiko
Ugai, Hiroyuki
Tekin, Cumhur
Toker, Sarper
Colombo, Nicoletta
Fujiwara, Keiichi
Hasegawa, Kosei
ANNALS OF ONCOLOGY, 2022, 33 : S476 - S476
[2] KEYNOTE-826: PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
Colombo, N.
Dubot, C.
Lorusso, D.
Caceres, V.
Hasegawa, K.
Shapira-Frommer, R.
Tewari, K.
Salman, P.
Usta, E. Hoyos
Yanez, E.
Gumus, M.
de Mendoza, M. Olivera Hurtado
Samouelian, V.
Castonguay, V.
Arkhipov, A.
Toker, S.
Li, K.
Keefe, S.
Monk, B.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A364 - A364
[3] Pembrolizumab plus chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.
Tewari, Krishnansu Sujata
Colombo, Nicoletta
Monk, Bradley J.
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
De Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Toker, Sarper
Keefe, Stephen Michael
Lorusso, Domenica
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826
Nishio, Shin
Yonemori, Kan
Usami, Tomoka
Minobe, Shinichiro
Yunokawa, Mayu
Iwata, Takashi
Okamoto, Aikou
Aoki, Yoichi
Itamochi, Hiroaki
Takekuma, Munetaka
Harano, Kenichi
Yamamoto, Keiko
Maruko, Takeshi
Ugai, Hiroyuki
Tekin, Cumhur
Colombo, Nicoletta
Fujiwara, Keiichi
Hasegawa, Kosei
Ushijima, Kimio
CANCER SCIENCE, 2022, 113 (11) : 3877 - 3887
[5] First-Line Pembrolizumab plus Chemotherapy Versus Placebo plus Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
Monk, Bradley J.
Colombo, Nicoletta
Tewari, Krishnansu S.
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
de Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Keefe, Stephen M.
Lorusso, Domenica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36) : 5505 - +
[6] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
Colombo, N.
Dubot, C.
Lorusso, D.
Caceres, V.
Hasegawa, K.
Shapira-Frommer, R.
Tewari, K. S.
Salman, P.
Hoyos, E.
Yanez, E.
Gumus, M.
De Mendoza, M. Olivera Hurtado
Samouelian, V.
Castonguay, V.
Arkhipov, A.
Toker, S.
Li, K.
Keefe, S. M.
Monk, B. J.
ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
[7] Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
Lorusso, D.
Colombo, N.
Dubot, C.
Hasegawa, K.
Shapira-Frommer, R.
Salman, P.
V. Caceres, M.
Samouelian, V.
Yanez, E.
Olivera, M.
Castonguay, V.
Arkhipov, A.
Li, K.
Toker, S.
Guemues, M.
Tekin, C.
Tewari, K. S.
Monk, B. J.
ANNALS OF ONCOLOGY, 2025, 36 (01) : 65 - 75
[8] KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Fujiwara, K.
Shapira-Frommer, R.
Alexandre, J.
Monk, B.
Fehm, T.
Colombo, N.
Caceres, M. V.
Hasegawa, K.
Dubot, C.
Li, J. J.
Stein, K.
Keefe, S. M.
Tewari, K.
ANNALS OF ONCOLOGY, 2019, 30
[9] PEMBROLIZUMAB plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: BEVACIZUMAB SUBGROUP ANALYSIS BASED ON PROTOCOL-SPECIFIED FINAL OVERALL SURVIVAL RESULTS OF KEYNOTE-826
Lorusso, Domenica
Colombo, Nicoletta
Monk, Bradley J.
Dubot, Coraline
Caceres, Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
De Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Li, Kan
Toker, Sarper
Tekin, Cumhur
Tewari, Krishnansu S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A1 - A1
[10] KEYNOTE-826: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
Tewari, K.
Caceres, M. V.
Alexandre, J.
Monk, B.
Fehm, T.
Colombo, N.
Hasegawa, K.
Dubot, C.
Li, J. J.
Stein, K.
Keefe, S.
Shapira-Frommer, R.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A162 - A162

← 1 2 3 4 5 →